Gene · 80339
Papers3,957
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
401 to 420 of 3,957
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics. | Proc Natl Acad Sci U S A | 2024 | 38657050 | PubTator, text mining | PubMed |
| PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. | Hepatology | 2024 | 38652636 | PubTator, text mining | PubMed |
| Factors associated with body weight gain and insulin-resistance: a longitudinal study. | Nutr Diabetes | 2024 | 38649714 | PubTator, text mining | PubMed |
| Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity. | Liver Int | 2024 | 38634702 | PubTator, text mining | PubMed |
| Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. | Nat Genet | 2024 | 38632349 | PubTator, text mining | PubMed |
| Lipid-Lowering Meroterpenoids Penihemeroterpenoids A-F from Penicillium herquei GZU-31-6 via Targeting the AMPK/ACC/SREBP-1c Signaling Pathway. | Org Lett | 2024 | 38630577 | PubTator, text mining | PubMed |
| Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease. | Clin Gastroenterol Hepatol | 2024 | 38604296 | PubTator, text mining | PubMed |
| Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort. | J Hepatol | 2024 | 38582304 | PubTator, text mining | PubMed |
| Associations of PNPLA3 and LEP genetic polymorphisms with metabolic-associated fatty liver disease in Thai people living with human immunodeficiency virus. | World J Hepatol | 2024 | 38577531 | PubTator, text mining | PubMed |
| Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant. | Scand J Gastroenterol | 2024 | 38563432 | PubTator, text mining | PubMed |
| 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population. | J Clin Exp Hepatol | 2024 | 38523737 | PubTator, text mining | PubMed |
| Risk factors associated with high-dose methotrexate induced toxicities. | Expert Opin Drug Metab Toxicol | 2024 | 38501267 | PubTator, text mining | PubMed |
| Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. | Semin Liver Dis | 2024 | 38499207 | PubTator, text mining | PubMed |
| The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants. | Hepatol Forum | 2024 | 38487739 | PubTator, text mining | PubMed |
| Altered lipid metabolism and the development of metabolic-associated fatty liver disease. | Curr Opin Lipidol | 2024 | 38484227 | PubTator, text mining | PubMed |
Non-Hispanic Black Persons With Nonalcoholic Fatty Liver Disease Have Lower Rates of Advanced Fibrosis, Cirrhosis, and Liver-Related Events Even After Controlling for Clinical Risk Factors and PNPLA3 Genotype. | Am J Gastroenterol | 2024 | 38483303 | PubTator, text mining | PubMed |
| PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans. | Gut | 2024 | 38458749 | PubTator, text mining | PubMed |
| Combination of heterozygous APOB gene mutation with PNPLA3 and TM6SF2 variants promotes steatotic liver disease, cirrhosis and HCC development. | Liver Int | 2024 | 38421084 | PubTator, text mining | PubMed |
| PARVB and HSD17B13 variants are associated with nonalcoholic fatty liver disease in children. | J Gastroenterol Hepatol | 2024 | 38418429 | PubTator, text mining | PubMed |
| High red meat consumption among PNPLA3 polymorphism carriers is associated with NAFLD in a multi-center cross-sectional study. | Eur J Clin Nutr | 2024 | 38403728 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/80339/papers?page=21